The patients enrolled in this study were using metformin with or without thiazolidinediones. The results showed sustained reductions in blood glucose control parameters, including haemoglobinA1C (HbA1c), for six months post-treatment.
“The improvements in HbA1c correlated with changes in multiple other clinical parameters suggesting that gastrin-based therapies, and specifically E1-INT, have the potential to re-engage the body’s natural mechanism to regulate glucose,” said Dr Tony Cruz, chairman and CEO of Transition. “The immediate goal is to optimize the dosing regimen in a larger phase II study.”